Obiltoxaximab

Obiltoxaximab
Monoclonal antibody
Type	?
Source	Chimeric (mouse/human)
Target	Bacillus anthracis anthrax
Clinical data
Trade names	Anthim
Identifiers
CAS Number	1351337-07-9
ATC code	None
ChemSpider	none
Chemical data
Formula	C₆₄₄₄H₉₉₉₄N₁₇₃₄O₂₀₂₂S₄₄
Molar mass	145.5 kg/mol

Obiltoxaximab is a monoclonal antibody designed for the treatment of exposure to Bacillus anthracis spores (etiologic agent of anthrax).^[1]

This drug was developed by Elusys Therapeutics, Inc.

References

↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Obiltoxaximab, American Medical Association.

Monoclonal antibodies for infectious disease and toxins

Fungal ("-fung-")

Human ("-fungu-")	Efungumab

Viral ("-v(i)[r]-")

Human ("-viru-")	Diridavumab Exbivirumab Foravirumab Libivirumab Rafivirumab Regavirumab Sevirumab Tuvirumab

Humanized ("-vizu-")	Felvizumab Motavizumab Palivizumab Suvizumab

Bacterial ("-ba(c)-")

Human ("-bacu-")	Nebacumab Panobacumab Raxibacumab

Mouse ("-baco-")	Edobacomab

Chimeric ("-baxi-")	Pagibaximab

Humanized ("-bazu-")	Tefibazumab^†

Toxin ("-tox(a)-")

Human ("-toxu-")	Actoxumab Bezlotoxumab

Chimeric ("-toxaxi-")	Obiltoxaximab

Humanized ("-toxazu-")	Urtoxazumab

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This article is issued from Wikipedia - version of the Sunday, February 28, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.